https://www.hmpgloballearningnetwork.com/site/pcn/news/most-patients-schizophrenia-relapse-free-paliperidone-palmitate-open-label-extension
In a 2-year open-label extension study of a 1-year randomized clinical trial, 95.6% of the participating patients with schizophrenia being treated with paliperidone palmitate (PP) remained relapse free for up to 3 years. Results from the study were published in JAMA Network Open.
“The low rate of relapse reported in this study highlights the important role that long-acting injectable (LAI) antipsychotics have as a treatment that can facilitate and support the recovery process,”
2 Likes
I think that this study is bias because invega did nothing for me at all
2 Likes
The study is a good preliminary study but there’s issues with it, like that the patients who were in it were already on the med for a year, and they didn’t have a control group of patients on other meds or no meds. It’s kind of sketchy in my opinion…
2 Likes